China News Service, Beijing, January 6 (Reporter Li Yanan) Lymphoma is one of the malignant tumors with the fastest growth rate and one of the top ten malignant tumors with the highest mortality rate in China.
The national "Major New Drug Creation" special achievement-BTK inhibitor Enokal (Obutinib Tablets) was recently approved for marketing, bringing new hope for lymphoma treatment.
Lymphoma is a malignant tumor originating from the lymphoid hematopoietic system. Among many malignant tumors, lymphoma is often ignored due to atypical symptoms (enlarged lymph nodes, fever, night sweats, weight loss, etc.).
Data show that about 93,000 people are diagnosed with lymphoma every year, and more than 50,000 people die from the cancer.
Today, with the development of diagnosis and treatment technology, lymphoma is no longer an incurable disease.
The advent of new targeted therapies and multiple immunotherapies has greatly improved the quality of life of patients.
Through decades of scientific research, scientists have discovered that BTK is a key component of the B cell receptor signaling pathway, the "core switch" of B cell growth, and BTK protein is the weakness of these cancer cells. If its activity is inhibited, it can Control the growth of malignant B cells.
"Our country used to rely on chemotherapy, and now the new method of lymphoma treatment is immune or targeted therapy. BTK is an ideal target for the treatment of malignant B-cell lymphoma. Because BTK small molecule inhibitors have very good specificity, they are The treatment of malignant tumors and some B-cell immune diseases has shown very good advantages." said Li Jianyong, director of the Department of Hematology of the First Affiliated Hospital of Nanjing Medical University: "This time, the national Class 1 innovative drug independently developed by Nuocheng Jianhua— —Inokal (Obutinib) is a new type of BTK inhibitor targeted drug, its effectiveness and safety are significantly higher than similar imported drugs, and it is expected to become a new anti-cancer weapon for doctors and patients."
Song Yuqin, deputy director of the Department of Lymphatic Oncology, Peking University Cancer Hospital, said: “In clinical trials, most patients are in the middle and advanced stages of the disease, but most of the patients have achieved significant tumor remission after taking abutinib. Under the condition of taking medicine, it can achieve BTK target inhibition efficiently, which has better safety and effectiveness advantages for the treatment of patients. I am very pleased to witness the good safety and excellent performance of the new BTK inhibitor in clinical studies Efficacy. I believe that its approval for marketing in the country can further improve the quality of life of patients."
At present, malignant tumors are one of the main public health problems that seriously threaten the health of the Chinese population, especially lymphoma, gastric cancer, lung cancer, colon cancer, breast cancer and other cancers, which are among the top ten malignant tumor mortality rates, and the prevention and control situation is still severe.
Since the implementation of the national "Major New Drug Creation" project, innovative drugs have been continuously developed to solve the ten major diseases that seriously affect the health of Chinese patients, including malignant tumors, and have brought more new treatment options for Chinese patients.
Ma Jun, director of the Harbin Institute of Hematology and Tumor, said: "Obutinib is a BTK inhibitor independently developed by a local biomedical company. The clinical research results show good efficacy and safety. Abutinib targets BTK targets. Occupy rate of nearly 100%, and the difference between individuals is small, and it has no obvious inhibitory effect on other kinases. While ensuring the curative effect, it effectively avoids the adverse reactions caused by off-target effects. In addition, obritinib achieves 150 times a day Oral administration of milligrams can ensure a stable and long-lasting high BTK occupancy rate for 24 hours, which brings convenience to patients' continuous treatment."
Professor Wu Depei, Director of the Department of Hematology of the First Affiliated Hospital of Soochow University, said: “As a result of local innovation, it signifies that we can develop new drugs with breakthrough advantages for Chinese patients and contribute Chinese wisdom to the world. Thanks to national policy incentives, my country’s innovation The development of the pharmaceutical industry has entered a new stage. I believe that in the future, we will continue to provide corresponding policy support to accelerate the implementation and transformation of results." (End)